Skip to main content
. 2017 Oct 17;41(2):229–237. doi: 10.1007/s40264-017-0596-0

Table 2.

Adverse events leading to discontinuation of bevacizumab (≥2% incidence)

Adverse event EB patients (n = 75) Median time to bevacizumab discontinuation (months)
Any event 32 (42.7) 8.2
Proteinuria 12 (16.0)
Epistaxis 3 (4.0)
Hypertension 2 (2.7)
Hemorrhoidal hemorrhage 2 (2.7)

Data are presented as n (%)

EB erlotinib plus bevacizumab